Objective To estimate the incidence of herpes zoster (HZ) and the incremental healthcare resource utilisation (HRU) and costs ...

Objective This post hoc analysis compared anifrolumab 300 mg every 4 weeks with placebo on rash and arthritis measures with different stringency in patients with moderate to severe SLE (phase IIb; ...

Objective There is a need to identify concerns unique to patients with cutaneous lupus erythematosus (CLE), which may not be captured by current common-practice dermatological quality-of-life tools.

Objectives To estimate the incidence and prevalence of SLE in Italy, and to describe the demographic and clinical characteristics of patients with newly diagnosed SLE. Methods A retrospective cohort ...

Objectives Antiphospholipid syndrome (APS) is characterised by the presence of antiphospholipid antibodies (aPLs) and clinical outcomes of thrombosis and/or obstetric morbidity and is associated with ...

Objective Posterior reversible encephalopathy syndrome (PRES) is a clinicoradiological diagnosis that can be associated with SLE. The clinical presentation, risk factors and outcomes of PRES in ...

Objective Delivery of a small for gestational age (SGA) infant is a common pregnancy complication among women with SLE. Although disease activity and autoantibodies such as anti-Smith and ...

Objective The question of sustained remission in SLE has been highlighted recently following data published on the use of chimeric antigen receptor-T cell therapy in SLE. With the review, we wanted to ...

Background Systemic lupus erythematosus (SLE) is a complex autoimmune and hereditary disease. We found that the mutation rs13306575 located in NCF2 is associated with the lupus phenotype, and we aim ...

Background Belimumab and low dose IL2 (Ld-IL2) has been identified effective in the treatment of systemic lupus erythematosus (SLE). However, the application of combined therapy for SLE has not been ...

Background and aims Type I interferons (IFN-I) are central to the pathogenesis of systemic lupus erythematosus (SLE). BDCA2 is a plasmacytoid dendritic cell (pDC)-specific receptor that, upon ...

Background Systemic lupus erythematosus (SLE) is a complex disease caused by interplay of genetic predisposition and environmental triggers. Strong genetic component in lupus supported by familial ...